Hidradenitis suppurativa (HS), sometimes known as acne inversa or Verneuil's disease, is a long-term dermatological condition characterized by the occurrence of inflamed and swollen lumps. These are typically painful and break open, releasing fluid or pus. The areas most commonly affected are the underarms, under the breasts, perineum, buttocks, and the groin. Scar tissue remains after healing. HS may significantly limit many everyday activities, for instance, walking, hugging, moving, and sitting down. Sitting disability may occur in patients with lesions in the sacral, gluteal, perineal, femoral, groin or genital regions. Prolonged periods of sitting down can also worsen the condition of the skin of these patients.
The exact cause is usually unclear but believed to involve a combination of genetic and environmental factors. About a third of people with the disease have an affected family member. Other risk factors include obesity and smoking. The condition is not caused by an infection, poor hygiene, or the use of deodorant. Instead, it is believed to be caused by hair follicles being obstructed, with the nearby apocrine sweat glands being strongly implicated in this obstruction. The sweat glands may or may not be inflamed. Diagnosis is based on the symptoms.
No cure is known, though surgical excision with wet-to-dry dressings, proper wound care, and warm baths or showering with a pulse-jet shower may be used in those with mild disease. Cutting open the lesions to allow them to drain does not result in significant benefit. While antibiotics are commonly used, evidence for their use is poor. Immunosuppressive medication may also be tried. In those with more severe disease, laser therapy or surgery to remove the affected skin may be viable. Rarely, a skin lesion may develop into skin cancer.
If mild cases of HS are included, then the estimate of its frequency is from 1âÂÂ4% of the population. Women are three times more likely to be diagnosed with it than men. Onset is typically in young adulthood and may become less common after 50 years old. It was first described between 1833 and 1839 by French anatomist Alfred Velpeau.
Although hidradenitis suppurativa is often called acne inversa, it is not a form of acne. Hidradenitis suppurativa lacks the core defining features of acne, such as the presence of closed comedones and increased sebum production.
The exact cause of hidradenitis suppurativa remains unknown, and there has, in the recent past, been notable disagreement among experts in this regard. The condition, however, likely stems from both genetic and environmental causes. Specifically, an immune-mediated pathology has been proposed, although environmental factors have not been ruled out.
Lesions will occur in any body area with hair follicles, and/or sweat glands. Areas such as the axilla, groin, and perineal region are more commonly involved. This theory includes most of these potential indicators:
The historical understanding of the disease suggests dysfunctional apocrine glands or dysfunctional hair follicles, possibly triggered by a blocked gland, which creates inflammation, pain, and a swollen lesion.
Several triggering factors should be taken into consideration:
Some cases have been found to result from mutations in the NCSTN, PSEN1, or PSENEN genes. The genes produce proteins that are all components of a complex called gamma- (ó-) secretase. This complex cuts apart (cleaves) many different proteins, which is a crucial step in several chemical signaling pathways. One of these pathways, known as notch signaling, is essential for the normal maturation and division of hair follicle cells and other types of skin cells. Notch signaling influences normal immune system function. Studies suggest mutations in the NCSTN, PSEN1, or PSENEN genes impair notch signaling in hair follicles. Although little is known about the mechanism, abnormal notch signaling appears to promote the development of nodules and lead to skin inflammation. In addition, the composition of the intestinal microflora and as a consequence dietary patterns appear to play a role. Although dysbiosis of the cutaneous microbiome, apparent in HS, is not observed, the concurrent presence of inflammatory gut and skin diseases has led to the hypothesis of a gut-skin axis in which gut microbiota is implicated. Indeed, analysis of bacterial taxa in fecal samples from HS patients supports the possibility of a role for intestinal microbial alterations in this chronic inflammatory skin disease.
Precocious puberty is more common among children and adolescents with hidradenitis suppurativa (HS) compared to those without the condition, according to a recent case-control study. An analysis of the Explorys database revealed that pediatric patients with precocious puberty have double the risk of developing HS, even after adjusting for factors like demographic characteristics and body mass index (BMI).
Early diagnosis is essential in avoiding tissue damage. However, HS is often misdiagnosed or diagnosed late due to healthcare professionals not being aware of the condition or people not consulting with a physician. Globally, the diagnosis is delayed more than 7 years in average after symptoms appear. This is much longer than with other skin conditions.
Hidradenitis suppurativa presents itself in three stages. Due to the large spectrum of clinical severity and the severe impact on quality of life, a reliable method for evaluating HS severity is needed.
Hurley's staging system was the first classification system proposed and is still in use for the classification of patients with skin diseases (i.e., psoriasis, HS, acne). Hurley separated patients into three groups based largely on the presence and extent of cicatrization and sinuses. It has been used as a basis for clinical trials in the past and to determine appropriate therapy for patients. These three stages are based on Hurley's staging system, which relies on the subjective extent of the diseased tissue. Hurley's three stages of hidradenitis suppurativa are:
The Sartorius staging system is more sophisticated than Hurley's. Sartorius et al. suggested that the Hurley system is not sophisticated enough to assess treatment effects in clinical trials during research. This classification allows for better dynamic monitoring of the disease severity in individual patients. The elements of this staging system are:
Points are accumulated in the above categories and added to give a regional and total score. In addition, the authors recommend adding a visual analog scale for pain or using the dermatology life quality index (DLQI, or the 'skindex') when assessing HS.
Treatment depends upon the presentation and severity of the disease. Due to the poorly studied nature of the disease, the effectiveness of medications and therapies was unclear. Clear and sensitive communication from health care professionals, and social and psychological interventions can help manage the emotional impact of the condition and aid necessary lifestyle changes. In May 2023, the European Commission (EC) approved Cosentyx (secukinumab) for active moderate to severe hidradenitis suppurativa in adults.
Other possible treatments include the following:
Cryotherapy has demonstrated efficacy against the disease, with 88% of persistent lesions resolving in a clinical trial of 23 patients.
Warm baths may be tried in those with mild disease. Weight loss and smoking cessation are recommended.
When the process becomes chronic, wide surgical excision is the procedure of choice.
Wounds in the affected area do not heal by secondary intention, and immediate or delayed application of a split-thickness skin graft is an option. Another option is covering the defect with a perforator flap. With this technique, the (mostly totally excised) defect is covered with tissue from an area nearby. For example, the axilla with a fully excised defect of 15 ÃÂ 7 cm can be covered with a thoracodorsal artery perforator flap.. A less invasive excision procedure called Skin-Tissue-sparing Excision with Electrosurgical Peeling or "STEEP" has also been developed for treating moderate to severe disease.
The 1064 nm wavelength (near-infrared) laser for hair removal may aid in the treatment of HS. A randomized control study has shown improvement in HS lesions with the use of a .
A 2022 study reported that administration of Botulinum toxin resulted in either clinical improvement or improved quality of life in 96.8% (n = 30/31) of HS patients. The level of evidence was moderate. It concluded that the treatment was a safe and potentially effective alternative for hidradenitis suppurativa patients resistant to standard-of-care therapies.
In stage III disease, as classified by Hurley's staging system, fistulae left undiscovered, undiagnosed, or untreated can rarely lead to the development of squamous cell carcinoma in the anus or other affected areas. Other stage III chronic sequelae may also include anemia, multi-localized infections, amyloidosis, and arthropathy. Stage III complications have been known to lead to sepsis, but clinical data are still uncertain.
Endocrine diseases are more common in people who have HS. Diabetes mellitus may be both a causal factor contributing to the evolution and/or severity of HS and a consequence of inflammation in HS. Thyroid disorders are also more common in patients with HS.
HS is a painful and socially isolating condition that leads to a negative impact on mental health as well. A 2020 meta-analysis found that 21% of people with HS have depression, including major depression, and 12% have anxiety, including generalized anxiety disorder and a higher risk of suicide. A 2020 study found that people with HS have suicide rates more than double the rates in controls, and also have a higher risk of attempting suicide.
Estimates of the prevalence of HS vary worldwide, and there is no accepted generalization. In the US, the prevalence is estimated to be 0.1% while in Europe it is thought to be 1% or more.
In North America and Europe, women are three times more likely to have HS. However, in South Korea, men are twice as likely to have HS.
HS is the most prevalent in people in their 20s and 30s.
A surgeon from Paris, Velpeau, described an unusual inflammatory process with the formation of superficial axillary, submammary, and perianal abscesses, in a series of three publications from 1833 to 1839. One of his colleagues, also located in Paris, named Verneuil, coined the term about 15 years later. This name for the disease reflects the former pathogenetic model of acne inversa, which considered inflammation of sweat glands as the primary cause of hidradenitis suppurativa. In 1922, Paul Schiefferdecker suspected a pathogenic association between acne inversa and apocrine sweat glands. In 1956, Pillsbury postulated follicular occlusion as the cause of acne inversa, which they grouped together with acne conglobata and ("dissecting cellulitis of the scalp") as the "acne triad". Plewig and Kligman added another element to their acne triad, pilonidal sinus. Plewig et al. noted that this new "acne tetrad" includes all the elements found in the original "acne triad", in addition to a fourth element, pilonidal sinus. In 1989, Plewig and Steger introduced the term "acne inversa", indicating a follicular source of the disease and replacing older terms such as "Verneuil disease".
Hidradenitis suppurativa has been referred to by multiple names in the literature and various cultures. Some of these are also used to describe different diseases or specific instances of this disease.
HS can have a strong negative impact on people's lives, as well as physical and mental health. People with HS often feel stigmatized and embarrassed by their condition. Many try to hide the symptoms, which can lead to impaired relationships and social isolation. A multidisciplinary approach by healthcare professionals, social support networks, and psychological interventions can contribute to a better quality of life. Compared to other skin diseases, HS has one of the highest Dermatology Life Quality Index (DLQI) scores.